Can melatonin reduce the severity of post-COVID-19 syndrome?




antioxidant status, cytokines, dose, free radicals, stress


This short review aimed at (i) providing an update on the health benefits associated with melatonin supplementation, while (ii) considering future potential research directions concerning melatonin supplementation use relative to Coronavirus disease of 2019 (COVID-19). A narrative review of the literature was undertaken to ascertain the effect of exogenous melatonin administration on humans. Night-time melatonin administration has a positive impact on human physiology and mental health. Indeed, melatonin (i) modulates the circadian components of the sleep-wake cycle; (ii) improves sleep efficiency and mood status; (iii) improves insulin sensitivity; and (iv) reduces inflammatory markers and oxidative stress. Melatonin has also remarkable neuroprotective and cardioprotective effects and may therefore prevent deterioration caused by COVID-19. We suggest that melatonin could be used as a potential therapy in the post-COVID-19 syndrome, and therefore call for action the research community to investigate on the potential use of exogenous melatonin to enhance the quality of life in patients with post-COVID-19 syndrome.

graphical abstract



How to Cite

Souissi, A., Dergaa, I., Romdhani, M., Ghram, A., Irandoust, K., Chamari, K., & Ben Saad, H. (2023). Can melatonin reduce the severity of post-COVID-19 syndrome?. EXCLI Journal, 22, 173–187.



Review articles


Most read articles by the same author(s)